Rituximab-Induced Hepatitis C Virus Reactivation After Spontaneous Remission in Diffuse Large B-Cell Lymphoma

report of this adverse effect in humans. Because the numbers of patients treated with erlotinib and other EGFR inhibitors is expected to increase significantly worldwide and a significant number of patients may remain on long-term treatment, TM perforation owing to EGFR inhibition is a differential diagnosis to consider if these patients present with sudden hearing loss. Physicians and patients should be aware of this possible adverse effect and take it into consideration when prescribing the drug.